Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Claudia Gaefke

Internal Medicine Phoenix, AZ Medical Doctor

NPI 1568840270 CMS profile 1365381

300 W Clarendon Ave Ste 120, Ste 140, Phoenix, AZ 85013

Open in the dashboard

General payments

$4,516

255 records reported · program years 2019–2025

Research payments

$1,174

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claudia Gaefke of Phoenix, AZ is reported in the CMS Open Payments database as having received $4,516 across 255 general payments and $1,174 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,116 116
2024 General $1,010 59
2023 General $800 50
2022 General $127 9
2021 General $20 1
2020 General $59 3
2019 General $384 17
2019 Research $1,174 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claudia Gaefke
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Claudia Gaefke were reported at $2,116. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Claudia Gaefke Internal Medicine median Middle half National median
2019 $384 $159 $48–$570 $163
2020 $59 $119 $33–$402 $114
2021 $20 $135 $37–$521 $132
2022 $127 $141 $42–$496 $149
2023 $800 $149 $45–$519 $160
2024 $1,010 $154 $47–$537 $164
2025 $2,116 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $942 87 payments
  2. AstraZeneca Pharmaceuticals LP $925 13 payments
  3. Genzyme Corporation $494 39 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $383 19 payments
  5. Novartis Pharmaceuticals Corporation $374 17 payments
  6. CSL Behring $319 18 payments
  7. Grifols USA, LLC $287 13 payments
  8. ADMA BioManufacturing LLC $129 12 payments
  9. Regeneron Healthcare Solutions, Inc. $113 7 payments
  10. GC Biopharma USA, Inc. $78 4 payments
  11. Other $472 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,340 241 payments
  2. Consulting Fee $118 11 payments
  3. Education $58 3 payments
Products named General payments · program years 2019–2025
  1. AIRSUPRA $758 8 payments
  2. FASENRA $716 6 payments
  3. DUPIXENT $681 52 payments
  4. TRELEGY ELLIPTA $490 45 payments
  5. TEZSPIRE $453 2 payments
  6. BREZTRI $430 3 payments
  7. NUCALA $406 39 payments
  8. CUVITRU $289 15 payments
  9. Xembify $287 13 payments
  10. Rhapsido $205 5 payments
  11. Other $1,498 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,174 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

760

Median for Allergy/ Immunology: 449

Drug cost

$311,476

Median for Allergy/ Immunology: $169,700

Branded share of claims

38.8%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucala Mepolizumab Brand 30 $109,618
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $86,320
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 73 $65,143
Qvar Redihaler Beclomethasone Dipropionate Brand 44 $12,804
Breo Ellipta Fluticasone/Vilanterol Brand 14 $9,540
Arnuity Ellipta Fluticasone Furoate Brand 24 $8,556
Epinephrine Generic 32 $7,153
Advair Hfa Fluticasone Propion/Salmeterol Brand 15 $6,197
Azelastine Hcl Generic 54 $1,617
Montelukast Sodium Generic 129 $1,247

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$60,962

Medicare's payments for the services billed

Medicare patients

218

Average age 74

Services billed

7,508

148 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 64%
Ischemic heart disease 28%
Diabetes 26%
Depression 23%
Osteoporosis 23%
Chronic kidney disease 21%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $151
  • Regeneron Healthcare Solutions, Inc. $23
$173 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $114
$114 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $102
$102 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $95
$95 73 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record